News
Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
Novo Nordisk's share price fell as well on Monday. However, the big pharma stock tumbled only around 5%, reflecting a much more muted impact on its business from scrapping the deal with Hims & ...
Novo Nordisk is pulling the plug on its partnership with Hims & Hers Health over claims that the telehealth company sold fake versions of the pharmaceutical firm's weight-loss drug, Wegovy.
Novo Nordisk will replace its chief executive, Lars Fruergaard Jorgensen, the company announced Friday, citing a sharp decline in its stock price that stemmed from increased competition for its ...
Wegovy-maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.
Novo Nordisk dished out an up-front payment of $200 million (not to mention potential milestone payments of up to $1.8 billion) to acquire UBT251, a triple agonist -- that is, a medicine that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback